DYNAVAX TECHNOLOGIES CORP
DelistedCIK 1029142fmd_1YF8WAP6DGR8EBHZYYX009VFQ2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2025, 63 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 4 | 11 | 0 | 8 | 35 | 47 | 439 | 723 | 232 | 277 |
| Net interest income | – | – | – | – | – | – | – | 5 | 0 | 0 |
| Research and development | 87 | 84 | 65 | 75 | 62 | 29 | 32 | 47 | 55 | 62 |
| Selling, general and administrative | 22 | 37 | 27 | 65 | 75 | 79 | 100 | 131 | 153 | 170 |
| Total operating expenses | 109 | 122 | 96 | 162 | – | – | – | – | – | – |
| Operating income | (105) | (111) | (96) | (153) | (135) | (68) | 134 | 284 | (37) | (4) |
| Interest expense | 1 | – | – | 9 | 17 | 19 | 11 | 7 | 7 | 7 |
| Interest and investment income | 0 | 1 | 1 | 4 | 3 | 1 | 0 | 8 | 32 | 36 |
| Other non-operating income (expense) | 0 | (2) | (0) | (0) | 1 | (1) | 1 | 0 | (0) | 0 |
| Income before taxes | (107) | (112) | (95) | (153) | (153) | (75) | 78 | 294 | (4) | 31 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 4 |
| Net income from continuing operations | (107) | (112) | (95) | (153) | (153) | (75) | 77 | 293 | (6) | 27 |
| Net income | (107) | (112) | (95) | (159) | (153) | (75) | 77 | 293 | (6) | 27 |
| Net income to common shareholders | (107) | – | (95) | (159) | (156) | (75) | 72 | 293 | (6) | 27 |